[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,69,106,129,152,173,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640590","inhale-and-exhale-breath-holds-to-improve-the-radiation-therapy-accuracy-in-people-with-upper-abdominal-cancers-100640590",false,"NCT07594691","Inhale and Exhale Breath Holds to Improve the Radiation Therapy Accuracy in People With Upper Abdominal Cancers","Inhale and Exhale Breath Holds to Improve the Therapeutic Ratio in Upper Abdominal Cancers Treated With SBRT","INEX-RT P","Inclusion Criteria:\n\n* Age ≥ 18\n* Any patient undergoing radiation therapy for a cancer lesion in the abdomen in close proximity to OARs that is hypothesized to have differential displacement on inhale and exhale breath hold CT scans of the OAR relative to the tumor.\n* Patients need at least 3 fractions of RT\n* Critical OARs are within 2 cm of luminal GI structures, chest wall, or previous radiation fields\n* Able to receive and understand verbal and written information regarding study and able to give written informed consent\n\nExclusion Criteria:\n\n* Inability to perform inhale or exhale breath holds during standard workflow CT simulation evaluation","ALL","18 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective quality improvement study. The INEX RT P study will prospectively evaluate INEX RT R that optimizes radiation dose delivery to the target while minimizing dose to critical organs at risk (OAR) by treating patients with different phases of breath hold (inhale and exhale) during the same course of SBRT. 15 patients with abdominal cancer whom are expected to achieve a dosimetric advantage from this technique due to OAR proximity to target will be treated using INEX RT. Investigators hypothesize increasing the dose to the RT target by at least 10% while simultaneously decreasing or maintaining dose to adjacent critical OARs when using a combination of breath hold positions to purposefully vary the position of OARs during different fractions of the same treatment course, when compared to RT treatments planned on a single breath hold phase alone (present standard of care).",[27],"Abdominal Cancer",[29,30,31,32],"INEX RT","SBRT","Breath","Breath Hold Immobilization","RECRUITING","2026-05-26",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":37},"2026-05-25",{"date":41,"type":21},"2028-01-30",{"name":43,"class":44},"University Health Network, Toronto","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100562543","magnetic-resonance-imaging-mri-guided-stereotactic-adaptive-radiotherapy-for-targeting-abdominal-cancer-100562543","NCT06604533","Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer","A Randomized Phase II Trial - Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer","Inclusion Criteria:\n\n* Aged 18 years or older\n* Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease\\* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites:\n\n  1. Liver\n  2. Adrenal\n  3. Abdomino-pelvic lymph node\n  4. Other abdominal site e.g. pancreatic, renal.\n  5. Other pelvic site\n  6. Bony or lung is allowed only if in conjunction with an abdominal site above\n* De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent.\n\n  * Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site\n  * Controlled primary disease in de novo oligometastatic disease defined as primary tumour site treated with curative intent and no progression at primary site\n* Oligometastatic disease: Histological confirmation of primary malignancy (histological confirmation of metastasis is not mandatory but should be performed in any situation where there is any diagnostic uncertainty).\n* All oligometastatic sites treatable with SABR.\n\nOR\n\n* Patients with oligo-progressive \u002F oligo-persistent disease in maximum total of 2 oligo-progressive abdominal metastases and in a maximum 2 different organ systems\n* Visible imaging defined targets and suitable for treatment with SABR\n* Childs Pugh A to B7 (in case of liver treatment)\n* ECOG 0 -2\n* Patient consented\n\nExclusion Criteria:\n\n* Contra-indication to MRI\n* Previous high dose radiotherapy to a site requiring stereotactic treatment (including SIRTEX). Further SABR treatment of lesions previously treated with SABR or high dose radiotherapy is not permitted in this trial.\n* Substantial overlap with a previously treated high dose (definitive or stereotactic dose) radiation volume.\n* Primary prostate cancer, carcinoid tumours, germ cell tumours, lymphoma, small cell tumours\n* Pregnant women\n* Complete response of metastatic disease to systemic therapy (i.e. no target for SABR)\n* Competing medical co-morbidity with a more limited prognosis than the cancer diagnosis",{"count":54,"type":21},30,[24],"The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.",[27],"2026-05-05",{"date":60,"type":37},"2026-05-08",{"date":62,"type":37},"2025-07-07",{"date":64,"type":21},"2030-01",{"name":66,"class":67},"Australasian Gastro-Intestinal Trials Group","NETWORK",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100614687","phase-2-heated-versus-aerosol-based-laparoscopic-chemotherapy-for-cancer-that-has-spread-to-the-peritoneum-abdominal-lining-100614687","NCT07282834","Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)","Randomized Phase II Trial of Heated Vs. Pressurized\u002FAerosolized Chemotherapy (HIPEC vs. PIPAC) for Peritoneal Carcinomatosis","Charlie-2","Inclusion Criteria:\n\n1. Males or females age 18 to 80 years.\n2. Biopsy-proven or clinically suspected peritoneal carcinomatosis\n3. Receipt of at least three months of standard systemic chemotherapy prior with persistence of disease at the time of randomization\n4. Not a candidate for surgical cytoreduction at the time of laparoscopy\n5. Women at least 18 years of age of childbearing potential must have a negative urine\u002Fserum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.\n6. Must be able to read and understand English and consent for themselves\n\nExclusion Criteria:\n\n1. Patients who are eligible for definitive cytoreductive surgery at the time of enrollment\n2. Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary, or renal disease:\n\n   AST\u002FSGOT \\> 2.5 times the upper limit of normal ALT\u002FSGPT \\> 2.5 times the upper limit of normal Total bilirubin \\> 2.5 times the upper limit of normal Hemoglobin \\\u003C 7 gm\u002FdL White blood cell count \\\u003C 3,000\u002F mm3 Platelet count \\\u003C 50,000\u002Fmm3\n3. Any investigational drug use within 30 days prior to enrollment.\n4. Systemic therapy within 14 days prior to randomization\n5. Allergy or medical contra-indication to chemotherapy utilized in this study\n6. Medical contraindication to laparoscopic surgery or complex cytoreductive surgery\n7. Pregnant or lactating females.\n8. Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.","80 Years",{"count":79,"type":21},200,[81],"PHASE2","This research study aims to improve the treatment of Peritoneal Carcinomatosis (PC), a condition where cancer spreads within the abdomen. Patients with PC often experience significant pain and nutritional problems. Currently, there isn't a standard treatment approach, and doctors use different combinations of chemotherapy, surgery, and methods to deliver chemotherapy directly into the abdomen (intra-peritoneal or \"IP\" chemotherapy).\n\nThe study will compare two IP chemotherapy methods: HIPEC and PIPAC. HIPEC involves circulating heated chemotherapy through the abdomen during surgery, while PIPAC delivers chemotherapy as a pressurized aerosol during a laparoscopic procedure. Both methods aim to achieve the same goal, but they haven't been directly compared to see which is safer, more tolerable, more effective, and provides better value.",[84,85,27,86],"Peritoneal (Metastatic) Cancer","Peritoneal Carcinomatosis","Abdominal Cancer Patients",[88,89,90,91,92,93,94,95,96],"intraperitoneal","peritoneal cavity","mitomycin-C","PIPAC","HIPEC","Heated Intra-Peritoneal Chemotherapy","Pressurized Intraperitoneal Aerosol Chemotherapy","intra-abdominal","cytoreduction","2026-02-25",{"date":99,"type":37},"2026-02-27",{"date":101,"type":37},"2026-01-05",{"date":103,"type":21},"2040-11",{"name":105,"class":44},"Patrick Wagner, MD, FACS",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100620417","effectiveness-of-pain-management-interventions-in-patients-with-abdominal-and-pelvic-cancer-100620417","NCT07357350","Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer","Effectiveness of Pain Management Interventions in Patients With Abdominal and Pelvic Cancer in a Tertiary Care Hospital: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients with chronic pain due to abdominal and pelvic cancer\n* Both Male and Female\n* Ages18-65 years\n* Patients who with recurrence or metastasis\n\nExclusion Criteria:\n\n* Patients who refuse to give consent\n* Patients who were lost to follow up after initial visit or assessment\n* History of severe depression or psychiatric illness\n* History of surgical procedure due to cancer\n* Patients with DNR code","65 Years",{"count":115,"type":21},100,"OBSERVATIONAL","The goal of this prospective observational study is to observe the effectiveness of pain management interventions in patients with abdominal and pelvic cancer pain.\n\nThe main question\\[s\\] it aims to answer are:\n\n* The effectiveness of pain management interventions.\n* The frequency of pain intervention procedures and side effects and complications of pain management interventions",[27],"NOT_YET_RECRUITING","2026-01-15",{"date":122,"type":37},"2026-01-22",{"date":124,"type":21},"2026-01-16",{"date":126,"type":21},"2026-12-31",{"name":128,"class":44},"Aga Khan University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":45},"100094723","a-study-to-determine-whether-perioperative-energy-dynamics-correlates-with-postoperative-outcomes-100094723","NCT00493688","A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes","Inclusion Criteria:\n\n* Participants 18 years of age or older.\n* Participants with newly diagnosed esophageal and lung cancer undergoing neoadjuvant chemotherapy, radiation therapy, and\u002For immunotherapy.\n* Participants who have signed the consent form to participate in the study.\n* Participants must have been evaluated in the Perioperative Evaluation and Management (POEM) Center or by a staff Anesthesiologist.\n* All laboratory and diagnostic evaluations required or used to evaluate the patient must be completed. All participants must be approved to undergo anesthesia by the standards of the POEM Center.\n* No samples belonging to vulnerable populations (children, pregnant women, cognitively impaired adults or prisoners) will be allowed from participation.\n\nExclusion Criteria:\n\n* Participant is under age 18.\n* Participant is unwilling to sign consent.\n* Participant is unable to exercise (bedridden or wheel chair bound).\n* Participant is enrolled in another study deemed by the investigator to affect oxygen metabolic efficiency and not presently the standard of care at MDACC.\n* Participant's condition is deemed unsatisfactory for surgery after the preanesthetic evaluation.\n* Participant has had a myocardial infarction within three months of the preanesthetic evaluation or presents with new or unstable angina.\n* Participant has a history of a cerebrovascular accident or transit ischemic attacks within three months of the preanesthetic evaluation.\n* Participant has a history of a pulmonary embolic event within three months of the preanesthetic evaluation.\n* Participant is known to have acute or chronic deep vein thrombosis.\n* Participant is pregnant.",{"count":79,"type":21},"To validate a new method for assessing perioperative risk in the cancer patient undergoing major cancer surgery.\n\nIn this proposed study researchers will:\n\n1. Measure preoperative energy reserve capacity (fitness)\n2. Determine if postoperative morbidity is a function of perioperative cardiopulmonary gas exchange metabolism",[27,138],"Pelvic Cancer",[27,138,140,141,142],"Perioperative Energy Dynamics","Cardiopulmonary Exercise Testing","CPET","2026-01-06",{"date":145,"type":37},"2026-01-08",{"date":147,"type":37},"2005-10-30",{"date":149,"type":21},"2028-10-30",{"name":151,"class":44},"M.D. Anderson Cancer Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":45},"100508669","a-feasibility-study-of-mri-guided-stereotactic-ablative-radiotherapy-midsection-100508669","NCT05903430","A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)","A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy","MIDSECTION","Inclusion criteria:\n\n1. Have no MRI contra-indications.\n2. Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.\n3. Be able to give informed consent.\n4. Anticipated life-expectancy \\> 6 months.\n5. Not more than 3 oligmetastatic sites treated in total per patients.\n6. Performance status ≤ 2.\n7. Willing to attend follow-up and have details collected on prospective basis for a minimum of 1 year.\n\nExclusion criteria:\n\n1. Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.\n2. Unable to tolerate MRI scans.\n3. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.\n4. Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.\n5. Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).",{"count":161,"type":21},60,"To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.",[27,164],"Lung Cancer","2025-08-29",{"date":167,"type":37},"2025-09-05",{"date":165,"type":37},{"date":170,"type":21},"2027-01-29",{"name":172,"class":44},"The Christie NHS Foundation Trust",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":193,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":211,"locationsCount":45},"100591303","neurolytic-block-techniques-in-abdominal-visceral-cancer-pain-100591303","NCT06978673","Neurolytic Block Techniques In Abdominal Visceral Cancer Pain","Comparison of Neurolytic Block Techniques for the Treatment of Abdominal Visceral Pain and Their Influence On The Quality of Life of Patients With Cancer","CONCERN","Inclusion Criteria:\n\nPatients aged 18 years or older Presence of localized visceral pain in the upper abdomen originating from cancer of the stomach, duodenum, distal esophagus, ascending or transverse colon, liver, biliary tract, or pancreas\n\nIneffectiveness of analgesic treatment with third-step opioids according to the WHO analgesic ladder, including:\n\nOpioids (≥ 60 mg\u002Fday of morphine equivalents) Antidepressants (tricyclic or dual-action), at any dosage Gabapentinoids, at any dosage Presence of side effects from analgesics that are difficult to manage with medication\n\nExclusion Criteria:\n\nPresence of ascites Presence of deep vein thrombosis Presence of hepatic failure: Child-Pugh class B or C Presence of renal failure: estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² Use of any anticoagulant medication\n\nClinical coagulation disorder, defined as:\n\nINR \\> 1.5 Prothrombin activity \\\u003C 70% or prothrombin time \\> 13.5 seconds aPTT \\> 40 seconds Cardiovascular failure: NYHA class III",{"count":182,"type":21},64,[24],"The neurolytic blocks of sympathetic chains are commonly used for the treatment of cancer-related pain. This study aims to compare celiac plexus neurolysis and splanchnic nerve neurolysis for the treatment of abdominal visceral pain and its influence on the quality of life of patients with cancer.",[186,27,187,188,189,190,191,192],"Cancer, Malignant Tumors","Cancer Pain","Visceral Pain","Cancer-related Pain","Pain Management","Celiac Ganglia","Sympathetic Ganglia",[194,195,196,197,198,199,200,201,202,203,204],"cancer pain","visceral pain","abdominal cancer","cancer","abdominal pain","cancer-related pain","pain management","neurolytic block","splanchnic nerve block","celiac plexus block","sympathetic neurolysis","2025-05-30",{"date":207,"type":37},"2025-06-03",{"date":205,"type":21},{"date":210,"type":21},"2026-12",{"name":212,"class":44},"Instituto do Cancer do Estado de São Paulo",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":236},"100456090","reconstruction-in-extended-margin-cancer-surgery-100456090","NCT05219058","Reconstruction in Extended MArgin Cancer Surgery","REMACS - Understanding the Impact of Perineal Reconstruction After Extended MArgin Cancer Surgery on Longer-term Quality of Life, Morbidity and Health Economic Outcomes - a Prospective Longitudinal Cohort Study","REMACS","Inclusion Criteria:\n\n* Male and female patients aged 18 or older\n* Patients that have undergone pelvic exenteration or abdominoperineal excision at participating sites, at any time, that have complete data (work package 1 - Colorectal Surgery Database)\n* Patients undergoing pelvic exenteration or abdominoperineal excision at participating sites (work package 2 - prospective study)\n* Patients that have already had pelvic exenteration or abdominoperineal resection that can speak English (work package 3 - mixed-methods study)\n\nExclusion Criteria:\n\n* Patients eligible for, but that are unfit, decline or are not offered abdominoperineal excision or pelvic exenteration surgery\n* Patients that undergo surgery by an intersphincteric abdominoperineal resection approach\n* Patients that are unable to complete the questionnaire over the telephone or online with a researcher\n* Patients unable or unwilling to provide informed consent\n* Patients that are prisoners in the custody of HM Prison Service or who are offenders supervised by the probation service",{"count":222,"type":21},236,"Advanced pelvic cancers are uncommon, with treatment being challenging. Around 4000 patients every year need treatment in the UK. Cancers can involve multiple organs and often need radiotherapy and chemotherapy before surgery. Surgery usually requires removal of multiple pelvic organs, including muscles, bone, and skin around the anus (the perineum). This can lead to complications relating to both the empty pelvis syndrome and closure of the perineal defect.\n\nReconstruction is challenging, with frequently occurring complications, reducing speed of recovery and quality of life. This study investigates complication frequency, quality of life and expenses following different reconstruction techniques. The investigators hope to improve patient and doctor decision-making in this area and find the best methods of reconstruction to improve outcomes.\n\nREMACS has three work packages:\n\n1. Maintenance of a database of patients undergoing colorectal surgery at Southampton and Salisbury Hospitals, including those undergoing extra-levator abdominoperineal excision and pelvic exenteration. This includes all routinely collected clinical data, imaging, health resource use, and patient reported outcome measures.\n2. A collaborative national prospective cohort study investigating morbidity, health resource use, longitudinal quality of life outcomes (EORTC QLQ-C30 and disease-specific modules) and quality adjusted life years. The investigators will also assess financial toxicity using the comprehensive score for financial toxicity.\n3. A qualitative study using semi-structured interviews to undertake a more complex evaluation of quality of life and patient experiences in patients that have recovered from their surgeries.\n\nThe last two work packages have now been funded by an NIHR Research for Patient Benefit Grant",[225,138,27,226],"Surgery--Complications","Quality of Life","2025-01-29",{"date":229,"type":37},"2025-01-31",{"date":231,"type":37},"2022-05-17",{"date":233,"type":21},"2028-01-01",{"name":235,"class":44},"University Hospital Southampton NHS Foundation Trust",18]